Literature DB >> 8206673

Trends in pancreatic cancer mortality in Europe, 1955-1989.

E Fernandez1, C La Vecchia, M Porta, E Negri, F Lucchini, F Levi.   

Abstract

Trends in death certification rates from pancreatic cancer over the period 1955-1989 were analyzed for 25 European countries (excluding the former Soviet Union and a few smaller countries). In 1985-1989, rates for males ranged between 5.3/100,000 (age-standardized world population) in Spain and 10.3/100,000 in Hungary and Czechoslovakia. Other high-mortality areas were located in Northern Europe (Finland, Iceland, Ireland, Denmark) and Central Europe (Austria, Poland, Germany), whilst mortality was lower in Southern Europe (Portugal, Greece). Between 1955 and 1989, mortality rates increased in all the countries considered, the change ranging between 6% in Scotland and 279% in Spain; the rises were higher in the Mediterranean and Eastern European countries than in Northern Europe. Among females, Nordic countries such as Iceland, Sweden and Denmark had the highest mortality rates in 1985-1989 (over 6/100,000) and, as for males, Southern Europe (Spain, Portugal, Greece) appeared as a low-mortality area (around 3/100,000). During the 1955-1989 period, upward trends were observed in all the countries studied, with the highest increase in Greece, Italy, Bulgaria, Poland and Spain. A negative correlation was observed between the percent change in mortality rates between 1955-1959 and 1985-1989 and the rate in 1955-1959 among both males (r = -0.95, p < 0.001) and females (r = -0.81, p < 0.001). Thus, a systematic levelling of rates was observed in most countries, with the exception of the UK and some Nordic countries, whose rates were already high in the late 1950s. Tobacco smoking and dietary factors could account for some of the generalized upward trends. Improved diagnostic and death certification of the disease might also partially explain the observed figures.

Entities:  

Mesh:

Year:  1994        PMID: 8206673     DOI: 10.1002/ijc.2910570605

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Regional variations in mortality rates of pancreatic cancer in China: results from 1990-1992 national mortality survey.

Authors:  Ke-Xin Chen; Peizhong Peter Wang; Si-Wei Zhang; Lian-Di Li; Feng-Zhu Lu; Xi-Shan Hao
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

2.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.

Authors:  Everardo D Saad; Marcel C Machado; Dalia Wajsbrot; Roberto Abramoff; Paulo M Hoff; Jacques Tabacof; Artur Katz; Sergio D Simon; René C Gansl
Journal:  Int J Gastrointest Cancer       Date:  2002

3.  The challenge of pancreatic cancer.

Authors:  James L Abbruzzese
Journal:  Int J Gastrointest Cancer       Date:  2003

4.  Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas.

Authors: 
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 5.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

6.  Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Authors:  J P Neoptolemos; P Baker; H Beger; K Link; P Pederzoli; C Bassi; C Dervenis; H Friess; M Büchler
Journal:  Int J Pancreatol       Date:  1997-04

7.  Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Authors:  Nicolas Tsavaris; Christos Kosmas; Helias Skopelitis; Panagiotis Gouveris; Petros Kopterides; Petros Kopteridis; Dioynissis Loukeris; Frantzeska Sigala; Alexandra Zorbala-Sypsa; Evangelos Felekouras; Efstathios Papalambros
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 8.  Pancreatic cancer - a continuing challenge in oncology.

Authors:  Attila Zalatnai
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

9.  Occupations with increased risk of pancreatic cancer in the Swedish population.

Authors:  J Alguacil; M Pollán; P Gustavsson
Journal:  Occup Environ Med       Date:  2003-08       Impact factor: 4.402

10.  Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.

Authors:  P Tassone; P Tagliaferri; C Viscomi; C Palmieri; M Caraglia; A D'Alessandro; E Galea; A Goel; A Abbruzzese; C R Boland; S Venuta
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.